Confronto

KPV vs. TB-500

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Guarigione

N. CAS

67727-97-3

nessun dato

Peso molecolare

342.4 g/mol

888 g/mol

Emivita

nessun dato

Sequenza

KPV

Ac-LKKTETQ

Meccanismo d'azione

KPV

KPV is the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). In preclinical models the inflammation-modulating activity is attributed predominantly to inhibition of the NF-κB and MAP-kinase signalling pathways, accompanied by reduced release of pro-inflammatory mediators. Cellular uptake via the peptide transporter PepT1 has also been described. The precise molecular mechanisms are not conclusively understood and not confirmed in humans.

TB-500

Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.

Base di evidenze

Evidenza più alta

Modello animale

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	KPV	TB-500
Australia	—	Vietato
Germania	Non approvato	Non approvato
Stati Uniti	Solo ricerca	Solo ricerca

Voci complete

Frequently asked questions

What is the difference between KPV and TB-500?: KPV is classified as "Guarigione", while TB-500 is classified as "Guarigione". KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, KPV or TB-500?: The highest available evidence level is "Modello animale" for KPV and "Modello animale" for TB-500. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of KPV and TB-500 in Germany and the United States?: Germania: KPV — Non approvato, TB-500 — Non approvato. Stati Uniti: KPV — Solo ricerca, TB-500 — Solo ricerca. These are factual summaries with source and review date on the individual pages.

Country

KPV

TB-500

Australia

—

Vietato

Germania

Non approvato

Stati Uniti

Solo ricerca

Frequently asked questions

What is the difference between KPV and TB-500?

KPV is classified as "Guarigione", while TB-500 is classified as "Guarigione". KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, KPV or TB-500?

The highest available evidence level is "Modello animale" for KPV and "Modello animale" for TB-500. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of KPV and TB-500 in Germany and the United States?

Germania: KPV — Non approvato, TB-500 — Non approvato. Stati Uniti: KPV — Solo ricerca, TB-500 — Solo ricerca. These are factual summaries with source and review date on the individual pages.